The experience of high flow nasal cannula in hospitalized patients with 2019 novel coronavirus–infected pneumonia in Chongqing, China

Abstract

Background The outbreak of a novel coronavirus (2019-nCoV)-infected pneumonia (NCIP)

Adaptation of a respiratory service to provide CPAP for patients with COVID-19 pneumonia, outside of a critical care setting, in a district general hospital

“…These studies supported the use of CPAP in individuals with ARF, strengthening resolve to meet the rising number of infections with operational changes that definitively involved the use of CPAP. [16][17][18] These findings have since been corroborated in other studies and use of CPAP incorporated into international guidelines. 19,20 We aimed to describe the adaptation of CUH to manage individuals with COVID-19 with CPAP outside of critical care, to describe the characteristics and any association with mortality.…”

Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections

“…COVID-19 is a recent and still ongoing pandemic that has spread quickly, overwhelming hospitals, increasing the demand for critical care services with a mortality rate in patients requiring advanced respiratory support ranging from 62 to 97% [14][15][16] , with nearly 25% of patients remaining critically ill 17 . In this context, an increasing number of publications are becoming available on the use of NRS 3,4,[10][11][12][13][16][17][18][19][20][21] , mostly from China 3, 4, 10-13, 16, 18, 20, 21 , but also from Italy 19 and USA 17 .…”

“…Noninvasive support was mainly delivered in ICU, apart from two studies that described its use outside the ICU settings in 20% 3 and 50% of their population 20 , respectively. The overall mean utilization rate among studies was 31% for HFNT 4,10,12,13,17,18,20 and 30% for NIV 4,[10][11][12][13][17][18][19][20][21] , with Wang et al 18 reporting a prevalent use of HFNT (63%) as initial respiratory support since that, because of the emergency, the clinical staff involved in patients' management had a heterogeneous background and little or no experience with NIV.…”

“…Failure rate was mainly explored in Chinese studies and varies widely as shown in the Supplementary material S3, ranging from 52% 21 to 92% 20 : however, data are not uniform since sometimes NIV was used as a rescue therapy after HFNT failure 18 .…”

Enfoque y manejo clínico de pacientes con enfermedad por SARS COV2 (Covid -19) en unidad de cuidado intensivo

“…Solo existe un estudio de tipo descriptivo que evalúa el uso de la CNAF (cánula de alto flujo) en la infección por COVID -19, que incluyó una muestra de 17 pacientes, sugiriendo algún grado de eficiencia en los Rev.Medica.Sanitas 23 (1): 14-33, 2020 pacientes con hipoxemia leve (Pa/Fi O2: 200 -300) y un aumento del riesgo de falla terapéutica en los pacientes con hipoxemia moderada y severa, con presentación de falla en el 57% y 79% de los casos respectivamente, mostrando adicionalmente el empeoramiento de los síntomas en estos dos subgrupos, lo cual contraindica su uso en pacientes con hipoxemia moderada y severa (Pa/FiO2 menor de 200) (43). Entonces:…”